Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe

Chevreul, Karine; Michel, Morgane; Brigham, Karen Berg; López-Bastida, Julio; Linertová, Renata; Oliva‐Moreno, Juan; Serrano‐Aguilar, Pedro; Paz, Manuel Posada de la; Taruscio, Domenica; Schieppati, Arrigo; Искров, Георги; Péntek, Márta; Schulenburg, J.-Matthias Graf von der; Kanavos, Panos; Persson, Ulf; Fattore, G

doi:10.1007/s10198-016-0781-6

Cited by 47 publications

(60 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is therefore important to quickly diagnose and treat this disorder, both for the comfort of CF patients' life and for socio-economic costs 44 . AIS, which was used in our study, is a good diagnostic tool for insomnia.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis

Tomaszek

Cepuch²,

Pawlik

2018

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis

Tomaszek

Cepuch²,

Pawlik

2018

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…The studies in this review included 2859 CF patients, with sample sizes ranging from 6 to 920. The largest sample came from a study looking at HRQOL across multiple European countries, conducted as part of the BURQOL-RD research network study [19].…”

Section: Study Characteristicsmentioning

confidence: 99%

Health State Utility Data in Cystic Fibrosis: A Systematic Review

Mohindru

Turner

Sach

et al. 2019

PharmacoEconomics Open

View full text Add to dashboard Cite

Introduction Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease progression. However, little is known about the health state utility (HSU) associated with CF disease states, adverse events, and changes in disease severity. Although HSU data have contributed to existing health economic modelling studies, a lack of such data have been highlighted. This systematic review aims to provide a summary of HSU-related research in CF and highlight related research gaps. Methods Online searches were performed in six databases and studies in any of the following categories were included: (1) estimation of HSUs in CF; (2) mapping studies between patient-reported outcome measures (PROMs) and HSUs; (3) economic evaluations on the management of CF that report primary HSU data; and (4) any CF clinical trial that reported HSU as an outcome. Results A total of 17 studies were reviewed, of which 12 provided HSU values for specific CF populations. The remaining five articles provided HSU data that were broken down by CF relevant health states, including lung transplantations, pulmonary exacerbation (PEx) events and forced expiratory volume in 1 s (FEV 1). Conclusion Current HSU data in CF are limited and there is considerable scope for further research, both in providing HSU values for CF and in investigating methods for HSU elicitation/evaluation in CF populations.

show abstract

“…Indeed, in BURQOL-RD participating countries, the reported prevalence ranged from 5.9 to 21.0 cases per 100,000 inhabitants, with additional disparities between regions within a same country [15]. Chevreul et al [16] estimated that the total average annual cost per patient with CF varied from €21,144 in Bulgaria to €53,256 in Germany. Direct healthcare costs ranged from €12,161 (Bulgaria) to €28,827 (Germany).…”

mentioning

confidence: 99%

Social/economic costs and health-related quality of life in patients with rare diseases in Europe

et al. 2016

Self Cite

View full text Add to dashboard Cite

Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe

Abstract: Our study highlights the burden of CF in terms of costs and decreased HRQOL for both patients and their caregivers throughout Europe.

Cited by 47 publications

References 23 publications

Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis

Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis

Health State Utility Data in Cystic Fibrosis: A Systematic Review

Social/economic costs and health-related quality of life in patients with rare diseases in Europe

Contact Info

Product

Resources

About